You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

GATIFLOXACIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Gatifloxacin patents expire, and when can generic versions of Gatifloxacin launch?

Gatifloxacin is a drug marketed by Apotex Inc, Hikma, Lupin Ltd, Rising, Sandoz, and Torrent. and is included in six NDAs.

The generic ingredient in GATIFLOXACIN is gatifloxacin. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gatifloxacin

A generic version of GATIFLOXACIN was approved as gatifloxacin by LUPIN LTD on August 28th, 2013.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GATIFLOXACIN?
  • What are the global sales for GATIFLOXACIN?
  • What is Average Wholesale Price for GATIFLOXACIN?
Drug patent expirations by year for GATIFLOXACIN
Drug Prices for GATIFLOXACIN

See drug prices for GATIFLOXACIN

Drug Sales Revenue Trends for GATIFLOXACIN

See drug sales revenues for GATIFLOXACIN

Recent Clinical Trials for GATIFLOXACIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shaheed Benazir Bhutto University Sheringal Dir UpperPhase 1
Khyber Medical University PeshawarPhase 1
Laboratorios Sophia S.A de C.V.Phase 3

See all GATIFLOXACIN clinical trials

Pharmacology for GATIFLOXACIN
Paragraph IV (Patent) Challenges for GATIFLOXACIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZYMAXID Ophthalmic Solution gatifloxacin 0.5 % 022548 1 2010-12-07
ZYMAR Ophthalmic Solution gatifloxacin 0.3 % 021493 1 2007-07-19

US Patents and Regulatory Information for GATIFLOXACIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc GATIFLOXACIN gatifloxacin SOLUTION/DROPS;OPHTHALMIC 079084-001 Aug 19, 2011 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Rising GATIFLOXACIN gatifloxacin SOLUTION/DROPS;OPHTHALMIC 206446-001 Jun 8, 2018 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hikma GATIFLOXACIN gatifloxacin SOLUTION/DROPS;OPHTHALMIC 203189-001 Sep 3, 2014 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Lupin Ltd GATIFLOXACIN gatifloxacin SOLUTION/DROPS;OPHTHALMIC 202653-001 Aug 28, 2013 AT RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Torrent GATIFLOXACIN gatifloxacin SOLUTION/DROPS;OPHTHALMIC 213542-001 Nov 3, 2021 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

GATIFLOXACIN Market Analysis and Financial Projection Experimental

Gatifloxacin Market Dynamics and Financial Trajectory

Introduction to Gatifloxacin

Gatifloxacin is a broad-spectrum antibiotic belonging to the fluoroquinolone class, widely used for treating various bacterial infections. It is available in several forms, including ophthalmic solutions, injections, tablets, and capsules.

Market Size and Forecast

The gatifloxacin market has been experiencing significant growth and is projected to continue this trend. As of 2023, the market was valued at USD 315.49 million and is expected to reach USD 331.32 million in 2024. By 2030, the market is forecasted to grow to USD 440.46 million, exhibiting a Compound Annual Growth Rate (CAGR) of 4.88%[4].

Growth Drivers

Several factors are driving the growth of the gatifloxacin market:

Rising Incidence of Bacterial Infections

The increasing prevalence of bacterial infections, particularly those resistant to other antibiotics, has boosted the demand for gatifloxacin. This rise in infections is a significant driver, as gatifloxacin's broad-spectrum efficacy makes it a preferred treatment option[2].

Technological Advancements in Drug Delivery Systems

Advancements in drug delivery systems have enhanced the efficacy and patient compliance of gatifloxacin. Improved formulations and delivery methods have made the drug more effective and easier to administer, contributing to its growing market[2].

Market Segmentation

The gatifloxacin market is segmented based on several criteria:

By Type

  • Purity ≥ 99%: This segment includes high-purity gatifloxacin API, which is crucial for pharmaceutical applications.
  • Purity < 99%: This segment includes lower purity gatifloxacin API, often used in research or less stringent applications[2].

By Application

  • Ophthalmic Drops: Gatifloxacin is commonly used in ophthalmic solutions for treating bacterial conjunctivitis and other eye infections[3].
  • Injection: Used for systemic infections, gatifloxacin injections are administered intravenously.
  • Tablet & Capsules: Oral forms of gatifloxacin are used for treating a variety of bacterial infections[2].

Market Dynamics

The gatifloxacin market is characterized by a dynamic interplay of supply and demand factors.

Drivers

  • Increasing Demand for Broad-Spectrum Antibiotics: The rise in antibiotic-resistant bacteria has increased the demand for broad-spectrum antibiotics like gatifloxacin.
  • Advancements in Healthcare Infrastructure: Improvements in healthcare infrastructure, especially in developing countries, have expanded the reach and accessibility of gatifloxacin[4].

Restraints

  • Regulatory Challenges: Strict regulatory requirements and the need for continuous clinical trials can act as restraints to market growth.
  • Side Effects and Safety Concerns: Like other fluoroquinolones, gatifloxacin can have side effects, which may limit its use in certain patient populations[4].

Opportunities

  • Emerging Markets: Growing healthcare needs in emerging markets present significant opportunities for the gatifloxacin market.
  • Research and Development: Continuous R&D in improving drug delivery systems and reducing side effects can open new avenues for market expansion[4].

Challenges

  • Competition from Other Antibiotics: The presence of other effective antibiotics can pose a challenge to the market growth of gatifloxacin.
  • Antibiotic Resistance: The ongoing issue of antibiotic resistance requires constant monitoring and adaptation, which can be a challenge for the market[4].

Financial Trajectory

The financial trajectory of the gatifloxacin market is promising, with steady growth projected over the next few years.

Current Valuation

As of 2023, the gatifloxacin market was valued at USD 315.49 million. This valuation is expected to increase to USD 331.32 million in 2024[4].

Future Projections

By 2030, the market is forecasted to reach USD 440.46 million, with a CAGR of 4.88%. Another projection indicates that the gatifloxacin API market will reach USD 597.3 million by 2032, exhibiting a CAGR of 4.20%[2][4].

Porter's Five Forces Analysis

To navigate the gatifloxacin market strategically, it is essential to analyze it using Porter's Five Forces:

Threat of New Entrants

The threat of new entrants is moderate due to the high barriers to entry, including regulatory approvals and significant R&D investments[4].

Bargaining Power of Suppliers

The bargaining power of suppliers is relatively low because there are multiple suppliers of gatifloxacin API, which reduces their negotiating power[4].

Bargaining Power of Buyers

The bargaining power of buyers is moderate, as they have some flexibility in choosing between different antibiotics, but gatifloxacin's unique benefits can retain customer loyalty[4].

Threat of Substitute Products

The threat of substitute products is high due to the availability of other antibiotics and potential new treatments in the pipeline[4].

Competitive Rivalry Among Existing Competitors

The competitive rivalry is high, as several pharmaceutical companies are involved in the production and marketing of gatifloxacin and other antibiotics[4].

Conclusion

The gatifloxacin market is poised for significant growth driven by increasing demand for broad-spectrum antibiotics, technological advancements, and expanding healthcare infrastructure. While regulatory challenges and side effects pose restraints, the market's financial trajectory indicates a robust future with projected valuations reaching USD 440.46 million by 2030.

Key Takeaways

  • The gatifloxacin market is valued at USD 315.49 million in 2023 and is expected to grow to USD 440.46 million by 2030.
  • The market is driven by the rising incidence of bacterial infections and technological advancements in drug delivery systems.
  • Key market segments include purity levels and applications such as ophthalmic drops, injections, and tablets/capsules.
  • The market faces challenges like regulatory hurdles and antibiotic resistance but offers opportunities in emerging markets and R&D.

FAQs

What is the current valuation of the gatifloxacin market?

The gatifloxacin market was valued at USD 315.49 million in 2023[4].

What is the projected CAGR of the gatifloxacin market from 2023 to 2030?

The projected CAGR is 4.88% from 2023 to 2030[4].

What are the key drivers of the gatifloxacin market?

The key drivers include the rising incidence of bacterial infections and technological advancements in drug delivery systems[2].

What are the main applications of gatifloxacin?

The main applications include ophthalmic drops, injections, and tablets/capsules[2].

What is the expected market size of the gatifloxacin API market by 2032?

The gatifloxacin API market is expected to reach USD 597.3 million by 2032[2].

Sources

  1. Market Research Intellect: Gatifloxacin Market Size and Forecast.
  2. The Market Intelligence: Gatifloxacin API Market Size, Share, Growth, and Industry Analysis.
  3. FDA: 021493 Gatifloxacin Clinical BPCA.
  4. 360iResearch: Gatifloxacin Market by Route of Administration, Form, Indication.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.